Betta Pharmaceuticals Co Ltd (300558.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE100002DD9

Price
40.21 CNY
Market cap
16.92 bn CNY
P/E (2025)
55.41
P/S (2025)
4.69
Dividend yield
0.37 %
Net margin
8.46 %
Return on equity (ROE)
4.63 %
Return on assets (ROA)
2.89 %

Betta Pharmaceuticals Co Ltd financials

Fiscal year20242025
Revenue2.89 bn CNY3.61 bn CNY
Gross profit2.35 bn CNY2.87 bn CNY
Operating income399.87 m CNY582.79 m CNY
EBIT476.96 m CNY490.50 m CNY
Net income402.57 m CNY305.33 m CNY
Diluted EPS – continuing operations0.96 CNY0.73 CNY

Full history since 2011, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Betta Pharmaceuticals Co Ltd

Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China and internationally. The company offers Icotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer (NSCLC); Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of NSCLC; and Bevacizumab, an antibody drug against human vascular endothelial growth factor that is used to treat NSCLC, colorectal cancer, and other solid tumor indications. It also develops BPI-D0316, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) targeting T790M mutation; EYP-1901, an investigational long-acting treatment for wet AMD, non-proliferative diabetic retinopathy, diabetic macular edema, and pmCNV; and MCLA-129, a bispecific antibody targeting both EGFR and c-Met. In addition, the company develops BPI-371153 for the treatment of patients with locally advanced or metastatic solid tumor or relapsed/refractory lymphoma; CFT8919, an in vitro and in vivo model of EGFR L858R-driven NSCLC; and Balstilimab, a human monoclonal antibody targeting programmed cell death protein 1 and an immune checkpoint inhibitor. Further, it develops a recombinant human serum albumin injection under the OsrHSA name; and products for the treatment of solid tumor under the BPI-452080, MRX2843, BPI-460372, BPI-221351, BPI-520105, BPI-572270, and BPI-585725 names. The company was founded in 2003 and is headquartered in Hangzhou, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.